Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gene mutation predict immunotherapy success? virtual trial aims to find out

NCT ID NCT04447651

Ongoing Knowledge-focused Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study explores whether people with metastatic solid tumors that have specific genetic mutations (SF3B1, U2AF1, or SRSF2) are more likely to respond to immunotherapy. The trial is conducted entirely online, using remote recruitment and a centralized tumor board to recommend treatments. It aims to see if this virtual approach is feasible for reaching patients and doctors who are not typically included in traditional clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
recommendation for treatment with immunotherapy
What this could lead to
If successful, this approach could help identify which patients with certain genetic mutations are more likely to benefit from immunotherapy, potentially improving treatment decisions.
What could go wrong
This is a small, early feasibility study with only 6 participants, so results may not apply broadly. The trial focuses on whether the virtual process works, not on proving the treatment itself is effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMOR SF3B1 GENE MUTATION SPLICEOSOME MUTATION SRSF2 GENE MUTATION U2AF1 GENE MUTATION

Contacts and locations

Locations

  • Johns Hopkins University

    Baltimore, Maryland, 21236, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.